Matt Hewitt
Stock Analyst at Craig-Hallum
(2.66)
# 1,944
Out of 5,163 analysts
43
Total ratings
54.05%
Success rate
2.67%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $12.44 | +189.39% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.10 | +96.72% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $1.98 | +203.03% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $18.36 | +74.29% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $34.40 | +86.05% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $202.91 | -31.00% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.34 | +2,838.58% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $12.51 | +139.81% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $0.82 | +753.87% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $114.20 | +75.13% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.79 | +458.66% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $5.37 | +458.66% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.28 | +140,546.98% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $12.44
Upside: +189.39%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.10
Upside: +96.72%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.98
Upside: +203.03%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $18.36
Upside: +74.29%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $34.40
Upside: +86.05%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $202.91
Upside: -31.00%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.34
Upside: +2,838.58%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $12.51
Upside: +139.81%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $0.82
Upside: +753.87%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $114.20
Upside: +75.13%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.79
Upside: +458.66%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $5.37
Upside: +458.66%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.28
Upside: +140,546.98%